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Background: It is unknown whether variability of estimated Glomerular Filtration Rate (eGFR) is a risk factor for
dialysis or death in patients with chronic kidney disease (CKD). This study aimed to evaluate variability of estimated
Glomerular Filtration Rate (eGFR) as a risk factor for dialysis or death to facilitate optimum care among high risk
patients.
Methods: A longitudinal retrospective cohort study of 70,598 Veterans Health Administration veteran patients with
diabetes and CKD (stage 3–4) in 2000 with up to 5 years of follow-up. VHA and Medicare files were linked to derive
study variables. We used Cox proportional hazards models to evaluate association between time to initial dialysis/
death and key independent variables: time-varying eGFR variability (measured by standard deviation (SD)) and eGFR
means and slopes while adjusting for prior hospitalizations, and comorbidities.
Results: There were 76.7% older than 65 years, 97.5% men, and 81.9% Whites. Patients were largely in early stage 3
(61.2%), followed by late stage 3 (28.9%), and stage 4 (9.9%); 29.1%, 46.8%, and 73.3%, respectively, died or had
dialysis during the follow-up. eGFR SDs (median: 5.8, 5.1, and 4.0 ml/min/1.73 m2 ) and means (median: 54.1, 41.0,
27.2 ml/min/1.73 m2) from all two-year moving intervals decreased as CKD advanced; eGFR variability (relative to
the mean) increased when CKD progressed (median coefficient of variation: 10.9, 12.8, and 15.4). Cox regressions
revealed that one unit increase in a patient’s standard deviation of eGFRs from prior two years was significantly
associated with about 7% increase in risk of dialysis/death in the current year, similarly in all three CKD stages. This was
after adjusting for concurrent means and slopes of eGFRs, demographics, prior hospitalization, and comorbidities. For
example, the hazard of dialysis/death increased by 7.2% (hazard ratio:1.072; 95% CI = 1.067, 1.080) in early stage 3.
Conclusion: eGFR variability was independently associated with elevated risk of dialysis/death even after controlling for
eGFR means and slopes.
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Chronic kidney disease (CKD) affects 15% of the U.S.
adult population and is associated with a high burden of
morbidities and mortality [1,2]. Patients with CKD are a
heterogeneous group characterized by varying rates of
progression to a devastating outcome such as end-stage* Correspondence: chin-lin.tseng@va.gov
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unless otherwise stated.renal disease (ESRD), likely due to presence/absence of
various risk factors [3-6]. Identifying risk factors of CKD
progression or death will directly benefit patients by help-
ing clinicians optimize health care and provide proper re-
ferral to multi-disciplinary clinics based on patients’ risk
profiles, hence may help reduce patients’ risk of morbid-
ities and mortality. Existing literature has provided sup-
port for many risk factors of CKD progression or death. A
greater degree of estimated glomerular filtration rate
(eGFR) downward trend was found to be associated with
higher mortality [7]. Other identified predictors of CKDThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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boratory test results (proteinuria, phosphorus, albumin,
hemoglobin), and comorbidities (diabetes, vascular dis-
ease, and hypertension) [3,7,8]. Recently, an algorithm was
proposed to combine those factors in predicting a patient’s
progression [9]. However, CKD progression is usually not
constant over time [10-12]. For example, acute kidney in-
jury—sudden deterioration of kidney function, is a critical
adverse event in CKD progression [13-15].
eGFR is often used in tracking CKD progression. Al-
though it is well recognized by clinicians that a single
eGFR may not provide sufficient and complete informa-
tion to one’s kidney function. For instance, two patients
with the same eGFR value may have different resilience
to kidney offense. Namely, other risk factors being equal,
an adverse event or an acute disease (i.e., a stimulus)
such as an infection may deteriorate kidney function
(less renal resilience) in one patient but not in the other
(greater resilience). In this study, we have proposed to
use variability of eGFR values to measure kidney resili-
ence, with larger eGFR variability indicating reduced kid-
ney resilience to stimuli, and considered the state of
kidney resilience as a potential risk factor of CKD pro-
gression. There are studies that have attempted to use
repeatedly measured eGFRs to model CKD progression
using different statistical approaches, including modeling
of non-linear trajectories [12,16-18]. A recent study
measured variability of kidney function using repeated
measured eGFRs [19] and found it to be associated with
increased risk of death in stage 3–5 CKD patients.
In this study, we also aimed to evaluate eGFR variabil-
ity as a risk factor; however, we have used different study
designs and methods, and included not only death but
also dialysis as the adverse CKD outcomes of interest.
Our hypothesis is that greater eGFR variability is associ-
ated with a higher risk of incurring dialysis or dialysis-
free death, independently of the CKD progression trend.
In essence, we believe although renal function decline
may be inevitable for patients with CKD, those with
similar decline rate of eGFR may be further differenti-
ated by degree of renal resilience, as reflected by eGFR
variability.
We chose to focus on CKD patients with coexisting
diabetes in the study. Patients with diabetes are at higher
risk of developing CKD. The risk of morbidity and mor-
tality increase in CKD patients with diabetes [20],
highlighting the importance of assessing and managing
risk factors associated with progression of CKD. Further-
more, both conditions have considerable costs and nega-
tive impacts to individuals, health care systems, as well as
the society as a whole, and they are increasingly prevalent.
In the Veteran Health Administration (VHA) health care
system, about one in five veterans have diabetes [21] and
30% of veterans with diabetes have CKD [22,23].Methods
Study design, data sources and study population
This was a longitudinal retrospective cohort study of
VHA veteran patients with diabetes in fiscal year (FY)
2000 (9/30/1999-10/1/2000) from a national research
database containing linked longitudinal patient records
of inpatient and outpatient services [21]. We determine
the baseline CKD status using two outpatient eGFR
values less than 60 ml/min/1.73 m2: the first (index)
eGFR value was identified in FY2000, followed by a subse-
quent qualifying eGFR 90 to 365 days apart from the index
eGFR. [23] eGFR was calculated with the four-variable
version of the Modification of Diet in Renal Disease equa-
tion [24,25]. The baseline period was the 12 months prior
to (and including) the date of the qualifying eGFR. Individ-
uals were followed through FY2004, with follow-up time
ranging between less than a year and close to five years.
Of the 653,064 VHA clinic users with diabetes in
FY2000, we excluded individuals according to different
criteria detailed in Figure 1. Patients enrolled in Medicare
Health Maintenance Organization (HMO) were excluded
because detailed Medicare HMO data is not routinely col-
lected by Center for Medicare and Medicaid Services. We
also excluded individuals with evidence of prior dialysis,
using International Classification of Diseases, Ninth
Edition, Clinical Modification (ICD-9-CM) diagnosis and
procedure codes, Current Procedural Terminology codes,
revenue codes (Medicare Part A), and VHA clinic stop
codes ([23]; Additional file 1). We determined CKD stage
using the qualifying eGFR based on the National Kidney
Foundation Kidney Disease Outcome Quality Initiative
(K/DOQI) criteria [24], and divided stage 3 into early
(eGFR 45–59 ml/min/1.73 m2) and late stage (eGFR 30–
44 ml/min/1.73 m2) [1,23]. We excluded individuals in
stage 5 CKD, who are close to developing ESRD.
The VHA New Jersey Healthcare System Institutional
Review Board approved the study. This study received a
waiver of consent from the facility Internal Review Board.
Outcome measures
The outcome was time from the date of the qualifying
eGFR to the event of dialysis or dialysis-free death,
whichever came first. The event time was censored if the
individual was enrolled in Medicare HMO or alive at the
end of FY 2004. Death information came from the VHA
Vital Status File [26]. We ascertained dialysis using the
method described above, but selected codes explicitly re-
ferring to dialysis treatment (see Additional file 1).
Independent variables
The primary exposure variable was variability in the out-
patient eGFR values. For each patient, we calculated
standard deviations (SDs), concurrent means, and slopes
of eGFR progression (derived from a linear regression)
Figure 1 Inclusion and exclusion steps for the creation of the study population, veteran patients with diabetes and chronic kidney disease
stages 3 and 4, USA. CKD – Chronic Kidney Disease; eGFR - estimated Glomerular Filtration Rate; FY – Fiscal Year (FY 2000: 10/1/1999-30/9/2000);
HMO: Health Maintenance organization; USA – United States of America. Grey-shaded boxes indicate patient subgroups (by chronic kidney disease
stage) included in the final study population.
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year moving intervals. In our analyses, the number of ac-
tual eGFR measurements per patient was at least two in
each of the five intervals. These variables were later used
as time-varying variables in Cox regression models.
Other independent variables included demographic vari-
ables (age, sex, and race/ethnicity), VHA priority status,
and clinical factors: prior hospitalization and medical co-
morbidities, all derived from the baseline period. The
VHA categorizes veteran enrollees into 1 of 8 mutually
exclusive priority groups [27] based on poverty level and
service connected disability. We regrouped patients into
four levels (severely disabled, moderately disabled, pov-
erty, and co-payment required). We applied the SelimComorbidity Index [28] to determine health status using
ICD-9-CM codes, including indicators of physical (cardio-
vascular and non-cardiovascular conditions separately),
and mental comorbidities. Cardiovascular conditions in-
cluded angina pectoris, myocardial infarction, congestive
heart failure (CHF), peripheral vascular diseases, and
stroke. Mental comorbidities included schizophrenia, de-
pression, bipolar disorder, anxiety, post-traumatic stress
disorder, and alcohol abuse.
Statistical analysis
We fitted the Cox proportional hazards models to evalu-
ate the association between eGFR variability and risk of
dialysis or dialysis-free death by each CKD stage. Prior
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ation/association among independent variables and
found little indication of co-linearity among variables
within each model.
Primary analysis: We divided the follow-up time into
yearly intervals and included the eGFR SDs, means and
slopes (derived from the two-year interval prior to each
yearly interval in the follow-up) as lagged time-dependent
covariates. Because higher values (hence greater means)
are usually associated with greater SDs, and lower values
(smaller means) are associated with smaller SDs, we in-
cluded both SDs and means (derived from the same time
intervals) as time-dependent covariates in the Cox models.
We also included interactions of eGFR SDs and slopes to
assess if the influence of eGFR variability differs with
changes in the slopes.
Sensitivity analysis: We conducted four sensitivity ana-
lyses to evaluate robustness of the findings from the pri-
mary analysis. First, regarding the length of the time
interval used to derive the time-varying eGFR SDs,
means and slopes, we re-fitted Cox regression models
using re-calculated time-varying eGFR SDs, means and
slopes from a one-year interval (prior to each yearly
interval in the follow-up). Second, we re-divided the
follow-up time into quarterly intervals and included
eGFR SDs, means and slopes from prior eight quarters
(two years) as time-dependent variables in Cox regression
models. Third, we examined the effect of extreme slopes
on our main findings by removing those with absolute
values greater than 36.5 or 25.0 ml/min/1.73 m2 per year;
this also simultaneously removed extreme SDs. Fourth, as
an alternative, for each patient in each defined time inter-
val we obtained the standard deviation of eGFR residuals
from the linear regression model used to obtained a eGFR
slope [29], and refitted Cox regression models. Results of
these sensitivity analyses were very similar and we chose
to present only findings of the main analysis.
Results
Of the 70,598 study patients, 61.2%, 28.9%, and 9.9%
were in early stage 3, late stage 3, and stage 4 CKD, re-
spectively. Table 1 also shows that they were largely men
(97.5%), and the mean age was 70(±9) years. There were
81.9% white, 14.2% African American, 2.3% Hispanics,
and 1.6% were of other racial groups. At the baseline,
36.6% had prior hospitalizations, 69.5% had cardiovascular
conditions, 98.3% had other non-cardiovascular condi-
tions, and 19.0% had mental comorbidities. Individuals in
stage 4 were more likely to be non-White, and had higher
rates of prior hospitalizations and comorbidities than
those in stage 3. During follow-up, 19,939 (28.3%) had
dialysis-free death, and 7,193 (10.3%) had dialysis. The rate
of dialysis or dialysis-free death was higher for patients
with more severe CKD: 29.1% for early stage 3, 46.8% forlate stage 3, and 73.3% for stage 4 CKD. Overall, the me-
dian follow-up time was 3.8 years (range: <0.01-4.8).
Generally, eGFR SDs and means decreased as CKD
advanced (Table 2). To account for the effect of mean in
interpreting SDs as a measure of variability, we have
supplemented the statistic of coefficient of variation (de-
fined as standard deviation divided by mean). The sum-
mary statistics show that eGFR variability (relative to the
mean) increased when CKD progressed. The median co-
efficient of variation was 10.9 for early stage 3, 12.8 for
late stage 3, and 15.4 for stage 4 CKD. The median eGFR
SDs from all of the two-year intervals were 5.8, 5.1, and
4.0 ml/min/1.73 m2 for early stage 3, late stage 3, and
stage 4, respectively. A downward trend of eGFRs was
observed for all CKD stages, with the magnitude in-
creasing as CKD progressed. The median slopes went
from −2.2 in early stage 3 to −3.5 ml/min/1.73 m2/year
in stage 4.
Figure 2 delineates the relationship between variability
in eGFRs (SDs) and presence/absence of the events of
dialysis or dialysis-free death. Across all three CKD
stages and for all follow-up years, individuals with events
always had significantly (p < 0.001 from t-tests) greater
average SDs than those without events, with the excep-
tion of the last four follow-up years in stage 4 (p > 0.05).
In Table 3, results from Cox regression models show
that a greater eGFR SD was associated with elevated risk
of dialysis or dialysis-free death, with or without adjust-
ing for other independent variables. For example, in
early stage 3, 1 ml/min/1.73 m2 increase in eGFR SD in
prior two years would increase the risk of dialysis or
dialysis-free death in the current year by 7.6% after
adjusting for the eGFR means and slopes (Model 1, ad-
justed hazard ratio (AHR) = 1.076; 95% CI = (1.071,
1.080)), or by 7.2% after additionally adjusting for other
demographic and clinical variables (Model 2, AHR =
1.072; 95% CI = (1.067, 1.080)). Similar associations were
found in the other CKD stages. Interactions of eGFR
SDs and slopes were not statistically significant.
Other independent variables were also significantly re-
lated to the risk of dialysis or dialysis-free death. If the
eGFR declined by 10 ml/min/1.73 m2 per year in previ-
ous two years, the risk would increase by 1.0% (Model 2,
AHR = 1.010; 95% CI = (1.003, 1.017)) in early stage 3
CKD, and 6.7% (Model 2, AHR = 1.067; 95% CI = (1.038,
1.096) in stage 4 CKD. Compared to patients younger
than 45 years old, patients 65 or older in early stage 3,
75 or older in late stage 3, and 85 or older in CKD 4
were at greater risk. Women tended to have lower risk
(AHR range: 0.63 to 0.66) than men. African Americans,
but not other racial/ethnic minorities were at higher risk
(1.07 to 1.14) than Whites. Individuals with severe ser-
vice connected disability also had higher risk (1.17 to
1.26) compared to others. As regards clinical factors,













Stage 4 CKD (N = 6,983;
9.9%)
N % N % N % N %
OUTCOMES
Dialysis 7,193 10.3 1,749 4 2,493 12.4 2,951 42.8
Dialysis-free death 19,939 28.3 10,844 25.1 6,957 34.4 2,138 30.5
CHARACTERISTICS
Age (in years)
<45 460 0.6 256 0.6 131 0.7 73 1
45-54 4502 6.4 2663 6.1 1218 6 621 8.9
55-64 11495 16.3 7275 16.9 3005 14.7 1215 17.3
65-74 29068 41.3 19374 45 7123 34.9 2571 37.5
75-84 23993 33.9 13108 30.2 8504 41.8 2381 33.6
85 and above 1080 1.5 552 1.3 406 2 122 1.8
Sex
Men 68818 97.5 42120 97.5 19889 97.6 6809 97.6
Women 1780 2.5 1108 2.5 498 2.4 174 2.4
Race
White 57713 81.9 35886 83.2 16625 81.6 5202 74.6
African American 10017 14.2 5687 13.2 2906 14.3 1424 20.5
Hispanic 1682 2.3 986 2.2 494 2.4 202 2.7
Others 1186 1.6 669 1.4 362 1.7 155 2.2
VHA priority status
Severely disabled 17013 24.1 9835 22.8 5116 24.9 2062 29.8
Moderately disabled 11469 16.2 7100 16.4 3348 16.3 1021 14.7
Poverty 33320 47.2 20749 48 9420 46.3 3151 44.7
Co-pay 7916 11.3 5009 11.6 2237 11.2 670 9.9
Missing 880 1.2 535 1.2 266 1.3 79 0.01
Prior hospitalizations
Yes 25820 36.6 14246 32.9 8276 40.5 3298 47.7
No 44778 63.4 28982 67.1 12111 59.5 3685 52.3
Cardiovascular conditions
Yes 49019 69.5 28666 66.2 15021 0.74 5332 76.9
No 21579 30.5 14562 33.8 5366 0.26 1651 23.1
Other physical conditions
Yes 69391 98.3 42372 98 20104 98.6 6915 99.2
No 1207 1.7 856 2 283 1.4 68 0.8
Mental comorbidities
Yes 13533 19 8467 19.5 3811 18.5 1255 17.8
No 57065 81 34761 80.5 16576 81.5 5728 82.2
Qualifying eGFR, mean ± sd
(in ml/min/1.73 m2)
46 ± 11 53 ± 4 39 ± 4 24 ± 4
Age (in years) 70 ± 9 70 ± 9 71 ± 9 69 ± 10
Notes: Because of rounding, percentages may not be equal to 100.
CKD: Chronic Kidney Disease; VHA: Veterans Health Administration; eGFR: estimated Glomerular Filtration Rate; qualifying eGFR is the subsequent eGFR 90 to
365 days apart from the index eGFR; sd: standard deviation.
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Table 2 Summary statistics of eGFRs from a series of two-year moving intervals
CKD stage Early 3 Late 3 Stage 4
Two-year moving
interval
(−1,0) (0,1) (1,2) (2,3) (3,4) All (−1,0) (0,1) (1,2) (2,3) (3,4) All (−1,0) (0,1) (1,2) (2,3) (3,4) All
eGFR
Variables
Variability median 6.0 6.2 5.7 5.3 5.3 5.8 5.5 5.7 4.8 4.4 4.4 5.1 4.6 4.6 3.4 3.1 3.2 4.0
(SD) Q1 3.8 4.4 4.1 3.7 3.6 4.0 3.5 3.8 3.4 3.0 2.9 3.4 2.8 3.0 2.4 2.0 2.1 2.6
Q3 8.6 8.6 7.7 7.5 7.6 8.1 8.8 8.4 6.8 6.2 6.3 7.5 7.9 7.1 5.0 4.6 4.8 6.5
IQR 4.8 4.2 3.6 3.8 4.0 4.1 5.3 4.6 3.4 3.2 3.4 4.1 5.1 4.1 2.6 2.6 2.7 3.9
Mean median 56.4 55.0 52.8 52 49.9 54.1 43.4 41.7 39.3 38.8 37.6 41.0 29.0 27.1 25.3 25.7 25.8 27.2
Q1 51.9 50.5 47.7 45.8 43.3 48.8 38.5 37.0 34.3 33.0 31.3 35.7 24.6 22.9 20.8 20.9 20.7 22.7
Q3 60.9 59.2 57.6 58 56.7 59.1 48.7 46.5 44.2 44.8 44.2 46.3 34.2 31.4 29.7 31.1 31.8 32.2
IQR 9.0 8.7 9.9 12.2 13.4 10.3 10.2 9.5 9.9 11.8 12.9 10.6 9.6 8.5 8.9 10.2 11.1 9.5
Coefficient of
variation
median 10.7 11.4 10.8 10.4 10.9 10.9 13.1 13.8 12.5 11.5 11.8 12.8 16.3 17.5 14.5 12.4 12.7 15.4
Q1 7.1 8.2 7.7 7.1 7.2 7.5 8.7 9.7 8.8 7.8 8.0 8.7 10.9 12.0 10.1 8.5 8.6 10.5
Q3 14.9 15.6 14.9 14.8 15.7 15.1 18.9 19.4 17.4 16.3 17.2 18.1 24.3 25.1 20.2 17.6 17.8 22.5
IQR 7.8 7.4 7.2 7.7 8.5 7.6 10.2 9.7 8.6 8.5 9.2 9.4 13.4 13.1 10.1 9.1 9.2 12.0
Slope median −3.6 −2.7 −1.3 −1.5 −1.2 −2.2 −5.9 −3.7 −1 −1.5 −1.2 −2.8 −6.8 −4.2 −1.1 −1.4 −1.2 −3.5
Q1 −9.3 −6.9 −5.1 −5.9 −4.6 −6.6 −13 −8.1 −4.4 −5.2 −4 −7.5 −14 −8.3 −3.7 −3.9 −3.2 −8.2
Q3 0.8 0.9 2.7 2.5 2 1.7 −0.8 −0.1 2.7 1.9 1.6 0.8 −2.4 −1.3 1.9 1.2 0.8 −0.3
IQR 10.1 7.8 7.8 8.4 6.6 8.3 12.2 8.0 7.1 7.1 5.6 8.3 11.6 7.0 5.6 5.1 4.0 7.9
CKD: Chronic Kidney Disease; For two-year moving interval, 0 denotes the baseline year, −1 denotes the year prior to the baseline, and 1 to 4 denote the number
of years in the follow-up period. eGFR: estimated Glomerular Filtration Rate. SD: standard deviation of an individual patient’s repeatedly measured eGFR values
from a two-year interval. Q1: 1st quartile. Q3: 3rd quartile. IQR: Inter-Quartile Range (=Q3 minus Q1). The unit for the eGFR slope variable is ml/min/1.73 m2/year.
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presence of cardiovascular conditions (1.21 to 1.52) and
mental comorbidities (early stage 3: 1.12; late stage 3:
1.10) at the baseline had elevated risks. The magnitude
of the AHR for these clinical factors somehow decreased
when CKD advanced.
Discussion
In this large cohort study of longitudinal outpatient
eGFR values, we found that greater variability in eGFRs,
measured by SDs in a dynamic/time-varying fashion
over the follow-up, was associated with elevated risk of
dialysis or dialysis-free death, even after controlling for
downward trends (slopes) in CKD progression and other
demographic and clinical factors. In all three CKD
stages, one ml/min/1.73 m2 increase in a patient’s SD of
eGFRs from prior two years was significantly associated
with about 7% increase in risk of dialysis/death in
current year (e.g., adjusted hazard ratio in early stage
3:1.072; 95% CI = (1.067, 1.080)). A recent study [19] of
stage 3-5 CKD patients also found the variability in re-
peatedly measured eGFRs to be associated with death,
although eGFR variability was measured differently andonly death was evaluated as the outcome in the study.
Both studies used VHA patients and have detailed
individual-level electronic health records in the VHA
health care system. However, our study had Medicare in-
formation for totality of data rather than VHA data
alone (most VHA patients are also Medicare eligible).
Additionally, we simultaneously evaluated eGFR slopes
and eGFR variability as potential risk factors by includ-
ing both as time-varying independent variables in the
statistical models. We found that a faster downward
eGFR progression was associated with increased risk of
CKD outcomes. This is consistent with the literature [7]
and the common knowledge among clinicians caring for
CKD patients.
Since our findings support the hypothesis of eGFR
variability (measured by standard deviation) being asso-
ciated with increased risk of dialysis or dialysis free
death, the key message for clinicians or health policy
makers is to consider using a simple statistic—standard
deviation, to assist in clinical care of CKD patients. We
have proposed to measure eGFR variability using the
statistic of standard deviation because it reflects the es-
sence of the concept and is familiar among clinicians
Figure 2 Average variability (measured by standard deviation) of estimated glomerular filtration rate variability by the follow-up year
and presence/absence of events for different chronic kidney disease stages. CKD – Chronic Kidney Disease. eGFR: estimated Glomerular
Filtration Rate .SD: standard deviation. Event: dialysis and/or dialysis-free death. Non-event: absence of dialysis and/or dialysis-free death. The error
bar is the standard error for the mean of the estimated Glomerular Filtration Rate variability (measured by standard deviation). Early stage 3 CKD:
P < 0.001 for all pairs of the contrast between events vs. non-events. Late stage 3 CKD: P < 0.001 for all pairs of the contrast between events vs.
non-events. Stage 4 CKD: P < 0.001 for the first year (p > 0.05 for the other years) of the contrast between events vs. non-events.
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Table 3 Adjusted hazard ratios for dialysis or dialysis-free death, by CKD stage
CKD stage Early stage 3 Late stage 3 Stage 4
Model 1 Model 2 Model 1 Model 2 Model 1 Model 2
AHR 95% CI AHR 95% CI AHR 95% CI AHR 95% CI AHR 95% CI AHR 95% CI
Low High Low High Low High Low High Low High Low High
Variables
eGFR variability (SD) 1.076 1.071 1.080 1.072 1.067 1.076 1.080 1.074 1.085 1.076 1.069 1.082 1.076 1.063 1.089 1.073 1.061 1.085
eGFR mean 0.963 0.961 0.966 0.968 0.965 0.970 0.950 0.948 0.953 0.951 0.948 0.954 0.928 0.922 0.933 0.927 0.922 0.933
eGFR slope (ml/min/1.73 m2
per year; 10 unit decrease)
1.011 1.004 1.018 1.010 1.003 1.017 1.007 1.004 1.009 1.008 1.006 1.011 1.064 1.035 1.094 1.067 1.038 1.096
Age (in years)
45-54 0.83 0.63 1.08 0.93 0.73 1.19 0.91 0.66 1.25
55-64 0.89 0.68 1.16 0.93 0.73 1.19 0.86 0.63 1.18
65-74 1.17 0.90 1.51 0.98 0.77 1.24 0.85 0.62 1.15
75-84 1.58 1.22 2.05 1.15 0.91 1.46 0.82 0.60 1.12
85 and above 2.71 2.05 3.57 1.78 1.37 2.31 1.07 0.75 1.52
<45 (reference) 1 1 1
Sex
Women 0.63 0.54 0.72 0.64 0.55 0.76 0.66 0.54 0.81
Men (reference) 1 1 1
Race/ethnicity
African American 1.07 1.02 1.13 1.10 1.03 1.16 1.14 1.06 1.22
Hispanic 0.96 0.85 1.09 0.91 0.79 1.05 0.93 0.79 1.10
Others 0.82 0.70 0.96 0.95 0.81 1.11 1.05 0.87 1.27
White (reference) 1 1 1
VHA priority status
Severely disabled 1.26 1.21 1.32 1.17 1.11 1.23 1.2 1.12 1.28
Moderately disabled 0.96 0.91 1.01 0.93 0.87 0.98 1.03 0.95 1.12
Co-pay required 0.79 0.74 0.84 0.86 0.8 0.93 0.92 0.83 1.02
Poverty (reference) 1 1 1
Prior hospitalization 1.56 1.50 1.62 1.48 1.42 1.55 1.28 1.21 1.37
Cardiovascular conditions 1.52 1.45 1.59 1.38 1.31 1.46 1.21 1.13 1.30
Mental comorbidities 1.12 1.07 1.17 1.10 1.04 1.16 1.06 0.99 1.14
CKD: Chronic Kidney Disease; Model 1: Containing eGFR variation (SD), mean, and slope variables; Model 2: Model 1 plus all other independent variables (age, sex, race/ethnicity, VHA priority status, presence of
hospitalization, cardiovascular conditions, and mental comorbidities); AHR: Adjusted Hazard Ratio; CI: Confidence Interval; All variables except for eGFR SD, mean and slope variables (time-varying variables) were
derived from the baseline period. The indicator of presence of non-cardiovascular conditions (Table 1) was not included in the modeling because about 99% of patients had the conditions; eGFR: estimated Glomerular
Filtration Rate; SD: standard deviation; VHA: Veterans Health Administration. The 880 people in the missing category of VHA priority status (Table 1) was not included for this analysis; We rounded the estimates for
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easily built into any existing systems of electronic health
records and the result (value) can be instantly made
available. Because this statistic is a summary measure of
the variability (non-stability) of renal function, it can be
used as a tool by clinicians in assessing CKD manage-
ment for a patient and assist in clinical decision making
for CKD care. For example, a clinician can compare a
patient’s current statistic with earlier results or the norm
(to be established as future work) and an elevated value
(indicating increased variability of renal function) may
alert the clinician to an acute kidney injury or other rea-
sons for such increased variability. This might direct cli-
nicians to look into the patient’s history of eGFR values
and health conditions, and to engage in active dialogues
with the patient regarding the patient’s recent changes of
health conditions and/or medications that may affect
kidney function. Standard deviation decreases as mean
decreases (also as seen in Table 2). Since the renal func-
tion of patients with CKD is expected to decline over
time (hence decreased eGFR values), one would expect
their standard deviations of eGFR values decrease as
well. Therefore, it is important to note that in comparing
a patient’s past and current eGFR SDs, an increased SD
would not be expected and may warrant more detailed
assessment.
Although variability in eGFR in CKD progression may
have not been well studied, the concept of variability has
been applied to different physiological markers in medi-
cine and is supported by various biological mechanisms.
For example, within-visit variability of blood pressure
was associated with stroke and all-cause mortality [30].
Heart rate variability predicted worst outcomes in peri-
operative and intensive care settings [31]. Furthermore,
home blood pressure and heart rate variability were asso-
ciated with cardiovascular events [32], and hemoglobin
(Hb) variability was associated with higher mortality
among patients with ESRD [29] or type 2 diabetes [33]. In
patients with type 1 diabetes, HbA1C variability was pre-
dictive of development of microalbuminuria, progression
of kidney disease and cardiovascular events [34].
In this study, we propose to measure eGFR variability
as a proxy for kidney resilience to stimuli. Greater vari-
ability of eGFR values over time means decreased renal
function and more stable eGFR values over time means
less damaging renal function. We caution not to confuse
this with the renal reserve (RR) test. The renal reserve
measures ability of a kidney to increase basal GFR after
a protein overload [35]; a larger value means a better
kidney ability/function. In CKD patients, renal reserve is
usually preserved but with a lower magnitude, suggest-
ing that remaining nephrons are able to maintain some
response to protein overload despite already being in a
state of hyperfiltration [35,36].Understanding predictors and pathways to ESRD/dia-
lysis in patients with CKD is important. A recent study
reported that patients were highly concerned with the
uncertainty of CKD progression and that physicians
were frustrated with their inability to predict the course
of CKD [37]. Uncertainty in predicting CKD progression
may limit clinicians’ ability in effective CKD management
and impair preparation for dialysis such as vascular access
placement for high-risk patients [38]. Understanding CKD
progression and identifying patients at high risk of adverse
outcomes is also valuable for health care resource and
program planning to improve CKD care. The uncertainty
rises mainly due to acute changes, eGFR variability, and/or
other characteristics of the course of CKD progression,
already stated above. Pathways other than linear slopes
have been described, but require a rather difficult applica-
tion of statistical modeling [12]. Prospective clinical stud-
ies may help to address these issues. We suggest that
regional health maintenance organizations with electronic
health records attempt to replicate our findings. We also
recognize that the general unavailability of electronic med-
ical records makes implementation of eGFR variability
problematic. However, the evaluation of individual level
longitudinal data using electronic records are consistent
with Federal policies to establish meaningful use criteria; it
provides the opportunity to simultaneously improve qual-
ity, safety, and efficiency and the results can provide deci-
sion support for national high-priority conditions.
We would like to note that there are existing studies ad-
dressing the question of changes in repeatedly measured
eGFR values. It was reported that patients in the quartile
with the greatest eGFR change were more likely to incur
death [39-41] and ESRD in one study [42] although not in
another [43]. In these studies, eGFR change was defined
as annual decline (measured as change in eGFR values
from two visits relative to the time elapsed between these
visits) [39] or percentage of change in eGFR values (mea-
sured as change in eGFR values from two visits relative to
the first eGFR value) [42] or both [40], or mean absolute
eGFR residual values [41,43]; patients then were assigned
into quartiles based on the value of eGFR change. The
findings of these studies were largely consistent with ours,
although different approaches were used.
There are a few unique features of this study: 1) the
advanced modeling of variability, slopes, and means of
repeated eGFR values over time as time-dependent vari-
ables (calculated in each two-year interval with sensitiv-
ity analyses) allows us to effectively test the hypothesis
and address the research question; 2) The explicit ad-
justment of eGFR slopes (as a time-dependent covariate)
allows us to evaluate whether there is an interaction be-
tween eGFR variability and CKD progression or only ex-
istence of their main effects; 3) inclusion of both dialysis
and death as adverse CKD outcomes for evaluation
Tseng et al. BMC Nephrology  (2015) 16:34 Page 10 of 11provides us overall understanding of risks of two critical
adverse outcomes of CKD progression in relation to
eGFR variability; and 4) evaluation of the associations by
CKD stage permits us to compare whether findings de-
pend on baseline renal status.
Our study has limitations. First, the findings of the
study may not be generalized beyond populations of
largely male, elderly and with diabetes; and CKD pa-
tients identified based on two eGFR values less than
60 ml/min/1.73 m2. Second, we were not able to identify
transient or temporary dialysis, resulting in censoring
some patients whose kidney function was resilient and
their creatinine values later improved during the follow-
up. Lastly, the primary goal of this study was to evaluate
eGFR variability as a new risk factor in CKD progression
in order to enhance clinical decisions by clinicians, and re-
sources planning by policy makers/administrators; none-
theless, assessing factors affecting eGFR variability as
future work is warranted. We suspect variability in eGFRs
may be related to medication changes, acute diseases (in-
fections, cardiac events, etc.) and hospitalizations (al-
though we included only outpatient creatinine values in
this study). Indeed, in an effort to assess eGFR variability
as a risk factor without the influence of some severe car-
diac conditions, we conducted two separate additional
analyses where we excluded 1) patients with a prior his-
tory of CHF at baseline or 2) patients with CHF anytime
during the study period (but prior to CKD outcomes if ap-
plicable). The findings remained similar.
Conclusions
In conclusion, this study provides support for evaluating
eGFR variability as an independent risk factor of dialy-
sis/death, regardless of CKD stage. It has important clin-
ical implication because patients may benefit from
monitoring of eGFR variability in addition to their rates
of eGFR decline.Additional file
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